ABT-199 is an anti-apoptotic protein Bcl-2 inhibitor that mimics BH3-only proteins, the native ligands of Bcl-2 and programmed cell death activators, repressing Bcl-2 activity and restoring apoptotic processes in tumor cells.
March 19, 2019 The FDA has placed a partial clinical hold on all clinical trials examining venetoclax (Venclexta) in multiple myeloma, halting enrollment of new patients on the studies, according to AbbVie, which jointly develops the BCL-2 inhibitor with Genentech (Roche). Read more...
| SparkCures ID | 24 |
|---|---|
| Developed By | AbbVie |
| Generic Name | Venetoclax |
| Additional Names | ABT-199 |
| Treatment Classifications |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
May 31, 2020
December 11, 2019
The phase III BELLINI trial (NCT02755597) demonstrated translocation(t)(11;14) and high BCL2 gene expression are predictive of response to treatment with the addition of venetoclax (Venclexta) to bortezomib (Velcade) plus dexamethasone in patients with relapsed/refractory multiple myeloma, according to the findings presented at the 2019 American Society of Hematology (ASH) Annual Meeting.
March 19, 2019
Living with a serious illness can come with many challenges. Getting Genentech medicines shouldn’t be one of them.
The Genentech Patient Foundation gives free Genentech medicine to people who don’t have insurance coverage or who have financial concerns.